RecruitingNot applicableNCT06388421
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Studying Pulmonary hypertension owing to lung disease and/or hypoxia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- United Therapeutics
- Principal Investigator
- United Therapeutics Global Medical Information
- Intervention
- Prospective study assessments(other)
- Enrollment
- 900 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (20)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Banner Health - University Medical Center Phoenix, Phoenix, Arizona, United States
- University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States
- National Jewish Health, Denver, Colorado, United States
- University of Florida, Gainesville, Florida, United States
- NCH Research Institute, Naples, Florida, United States
- Advent Health Medical Group Advanced Lung Disease, Orlando, Florida, United States
- Intercoastal Medical Group, Sarasota, Florida, United States
- Tampa General Hospital/University of South Florida Health, Tampa, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- Loyola University Medical Center, Maywood, Illinois, United States
- Advocate Christ Medical Center, Oak Lawn, Illinois, United States
- Ascension St. Vincent, Indianapolis, Indiana, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06388421 on ClinicalTrials.gov